In this article, Bora discusses its expansion efforts and plans to provide services in the United States. In the large molecule space, Bora offers comprehensive services from the development of mammalian cell lines through cGMP production of drug substance. Read the article
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) and Celltrion Asia Pacific Pte., Ltd. (“Celltrion”), a subsidiary of Celltrion Group Inc, have today announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region. The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, which is one of the...
Importance of equipment reliability Successfully manufacturing a drug product requires people, proper equipment, and materials. It’s the classic three-legged stool analogy. Even with well-trained staff and high-quality materials, if the equipment does not function as expected, or is not reliable, the final product can never be cost-effectively produced. Product quality will likely be compromised...
Extrusion Spheronization’s Expanding Influence as a Drug Manufacturing Driver Widely acknowledged as a predictable vehicle for the control, distribution and transportation of therapeutic agents around the body, E-S engineered formulations make a variety of common and emerging controlled release dose forms possible. These include fixed-dose combinations (FDCs), combined, modified release...